chemieunternehmen.com

Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-enter-into-exclusive-negotiations-for-a-major-multi-component-strategic-collaboration-5251

Evotec AG today reported financial results and corporate updates for the first nine months of 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-results-of-the-first-nine-months-of-2014-5249

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-as-part-of-its-multi-target-alliance-with-bayer-healthcare-5245

Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and–its-partners-awarded-public-grants-to-develop-new-drug-candidates-to-treat-multiple-sclerosis-5243

Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-takes-legal-steps-against-andromeda-biotech-ltd-5241

Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-jain-foundation-expand-collaboration-start-of-multiple-drug-screening-programmes-5239

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-update-on-diapep277r-5234

On Friday, the motor neuron research group took on the ALS Ice Bucket Challenge to help raise awareness for this rapidly progressive neurodegenerative disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotecs-motor-neuron-research-team-and-members-of-the-management-board-help-raise-awareness-for-als-disease-5232

Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV’s Malaria and Pathogen Box initiatives. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-medicines-for-malaria-venture-announce-a-long-term-compound-management-collaboration-5231